003850.KS
Latest Trade
21,450.00KRWChange
450.00(+2.14%)Volume
1,569,943Today's Range
-
21,900.0052 Week Range
-
30,100.00As of on the Korea Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 21,000.00 |
|---|---|
Open | 20,750.00 |
Volume | 1,569,943 |
3M AVG Volume | 40.89 |
Today's High | 21,900.00 |
Today's Low | 20,600.00 |
52 Week High | 30,100.00 |
52 Week Low | 7,638.07 |
Shares Out (MIL) | 49.74 |
Market Cap (MIL) | 1,117,974.00 |
Forward P/E | 32.51 |
Dividend (Yield %) | 0.47 |
S.Korea's Boryung Pharm Says Co-CEO Kim Eun-Sun Resigns For Personal Reason, Appoints An Jae-Hyun As New Co-CEO
Boryung Pharm to buy back shares at 5.57 bln won
Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Boryung Pharm Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The Company distributes its products in domestic and overseas markets.
Industry
Biotechnology & Drugs
Contact Info
Boryung Bldg.
136, Changgyeonggung-ro, Jongno-gu
03127
South Korea
+82.2.7088000
http://www.boryung.co.krExecutive Leadership
Eun Seon Kim
Chairman of the Board
Seung Ho Kim
Chairman
Jae Hyeon Ahn
Co-Chief Executive Officer, Director
Sam Su Lee
Co-Chief Executive Officer, Director
Yong Gwan Jeon
Vice President
Price To Earnings (TTM) | 36.84 |
|---|---|
Price To Sales (TTM) | 1.99 |
Price To Book (MRQ) | 3.14 |
Price To Cash Flow (TTM) | 20.85 |
Total Debt To Equity (MRQ) | 56.76 |
LT Debt To Equity (MRQ) | 50.64 |
Return on Investment (TTM) | 6.15 |
Return on Equity (TTM) | 4.66 |
* AGREES TO TERMINATE 85 BILLION WON ($70.09 million) WORTH CONTRACT WITH NOVARTIS' UNIT IN SOUTHEAST ASIA Source text for Eikon: https://bit.ly/2NwTDEF Further company coverage: ($1 = 1,212.6600 won)
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.